Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
RGNX vs DMAC: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
DMAC Captures Overall Composite Edge (46.3 HOLD vs 45.3 HOLD), While RGNX Leads 4–2 on Growth & Valuation Pillars
DMAC Overall Winner
6-Pillar Tally: RGNX 4 – 2 DMAC
Matrix Metrics: RGNX 2 – 5 DMAC
As of Nov 16, 2026, DiaMedica Therapeutics Inc. (DMAC) captures the overall head-to-head institutional edge over REGENXBIO Inc. (RGNX) on higher Unified Composite conviction (46.3/100 HOLD vs. 45.3/100 HOLD) after splitting the core matrix 5–2 (led by Growth & Scale, Profitability & Quality), while RGNX wins 4–2 across the 6-pillar growth and valuation breakdown. RGNX trades at $7.47 (N/M Forward P/E, -120.4% operating margin) versus DMAC at $8.41 (N/M Forward P/E, 0.0% operating margin).
- Growth vs. Quality Trade-Off: DMAC earns the overall head-to-head edge with a stronger Unified Composite Score (46.3/100 HOLD vs. RGNX 45.3/100 HOLD) and 1.74β · 98% Vol risk profile, whereas RGNX leads top-line expansion (-69.2% YoY revenue growth, 0.26x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
- Technical & Structure Timing Caution: RGNX is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.3); meanwhile DMAC trades in a Neutral technical trend (SURGE options phase, RSI 44.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About RGNX vs DMAC
RGNX
REGENXBIO Inc.
$7.47
-2.23% 1D
Market Cap
$500.9M
TTM Revenue
$154M
Forward P/E
N/M
Beta / 30D Vol
1.81β · 76% Vol
Unified Composite Score
45.3
HOLD
Tech 36.0
Fund 44.0
Flow 69.0
Mom 50.0
Weinstein Technical Phase
Distribution · Trim / tighten stop
DMAC
Head-to-Head Winner
DiaMedica Therapeutics Inc. Common Stock
$8.41
-4.27% 1D
Market Cap
$503.1M
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
1.74β · 98% Vol
Unified Composite Score
46.3
HOLD
Tech 30.0
Fund 51.0
Flow 65.0
Mom 60.0
Weinstein Technical Phase
Neutral · Hold
6-Pillar Scorecard Institutional Category Breakdown (RGNX 4 – 2 DMAC)
1. Valuation Multiples
RGNX
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
0.26x
N/M
EV / Revenue
3.1x
N/M
2. Growth & Scale
DMAC
Revenue Growth (YoY)
-69.2%
+0.0%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$154M
N/A
Market Cap
$500.9M
$503.1M
3. Profitability & Quality
DMAC
Gross Margin
-64.5%
N/A
Operating Margin
-120.4%
0.0%
Net Profit Margin
-113.9%
0.0%
Return on Equity (ROE)
-113.2%
-114.6%
4. Balance Sheet & Cash Flow
RGNX
Cash Generation (TTM)
-$155M
-$32M
Cash Flow Margin
-100.6%
N/A
Net Cash / Leverage
$29M Net Cash
$4.9M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
RGNX
Options Structure Phase
BREAKDOWN
SURGE
Current IV / %ile
349.6% (52nd %ile)
106.3% (14th %ile)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
ACCUMULATION · Distribution
NEUTRAL · Neutral
6. R&D & Supply-Chain Moat
RGNX
OpEx & R&D Intensity
55.9% of Rev ($86M)
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: RGNX (2) vs DMAC (5)| Institutional Metric | RGNX | DMAC | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $500.9M | $503.1M | Tie | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | -69.2% | +0.0% | DMAC | |
| Operating Margin (TTM) | -120.4% | 0.0% | DMAC | |
| Net Profit Margin | -113.9% | 0.0% | DMAC | |
| Return on Equity (ROE) | -113.2% | -114.6% | RGNX | |
| 52-Week Range Position | 19% ($5–$16) | 55% ($5–$11) | DMAC | |
| Beta / 30D Volatility | 1.81β · 76% Vol | 1.74β · 98% Vol | RGNX | |
| Unified Institutional Score | 45.3 / 100 (HOLD) | 46.3 / 100 (HOLD) | DMAC | |
| Trailing 12M Revenue (USD) | $154M | N/A | Scale | |
| Gross Profit Margin (TTM) | -64.5% | N/A | Quality | |
| PEG Ratio & EV / Revenue | 0.26x PEG · 3.1x EV/Rev | N/M PEG · N/M EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$155M ($29M Net Cash) | -$32M ($4.9M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
DMAC +3.29 pp
3M Horizon
DMAC +59.83 pp
6M Horizon
DMAC +15.94 pp
1Y Horizon
DMAC +91.08 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | RGNX Revenue | DMAC Revenue | RGNX Op. Margin | DMAC Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $220M | $0M | 40.3% | -1352.2% | RGNX |
| FY2019 | $40M | N/A | -422.9% | N/A | RGNX |
| FY2020 | $150M | N/A | -77.1% | N/A | RGNX |
| FY2021 | $470M | N/A | 34.0% | N/A | RGNX |
| FY2022 | $110M | N/A | -233.2% | N/A | RGNX |
| FY2023 | $90M | N/A | -297.1% | N/A | RGNX |
| FY2024 | $80M | N/A | -280.0% | N/A | RGNX |
| FY2025 | $170M | N/A | -94.6% | N/A | RGNX |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
RGNX
BREAKDOWN
Current IV
349.6%
IV Percentile
52nd %ile
Put/Call OI Skew
N/A
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
ACCUMULATION
Exact RGNX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
DMAC
SURGE
Current IV
106.3%
IV Percentile
14th %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact DMAC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
RGNX Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
55.9% of Rev ($86M)
90D Engineering Disclosures
0 Published
DMAC Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ RGNX vs DMAC Key Questions & Quantitative Answers
As of Nov 16, 2026, DiaMedica Therapeutics Inc. (DMAC) captures the overall head-to-head institutional edge over REGENXBIO Inc. (RGNX) on higher Unified Composite conviction (46.3/100 HOLD vs. 45.3/100 HOLD) after splitting the core matrix 5–2 (led by Growth & Scale, Profitability & Quality), while RGNX wins 4–2 across the 6-pillar growth and valuation breakdown. RGNX trades at $7.47 (N/M Forward P/E, -120.4% operating margin) versus DMAC at $8.41 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: DMAC earns the overall head-to-head edge with a stronger Unified Composite Score (46.3/100 HOLD vs. RGNX 45.3/100 HOLD) and 1.74β · 98% Vol risk profile, whereas RGNX leads top-line expansion (-69.2% YoY revenue growth, 0.26x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: RGNX is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.3); meanwhile DMAC trades in a Neutral technical trend (SURGE options phase, RSI 44.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
DMAC leads the Growth & Scale pillar: RGNX posts -69.2% YoY revenue growth and +0.0% YoY earnings growth on $154M TTM revenue (-64.5% gross margin, -120.4% operating margin), compared with DMAC at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), RGNX cumulative revenue shifted -22.7% while DMAC shifted N/A. In operating R&D and SG&A reinvestment, RGNX deploys 55.9% of Rev ($86M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DMAC.
RGNX screens cheaper on headline valuation multiples. RGNX trades at N/M Forward P/E, N/M Trailing P/E, 0.26x PEG, and 3.1x EV/Revenue (-100.6% FCF margin), whereas DMAC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RGNX (-113.2% ROE) versus DMAC (-114.6% ROE) capital efficiency.
In options market volatility and institutional positioning, RGNX carries 349.6% implied volatility (52nd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.81β · 76% Vol realized risk). By comparison, DMAC carries 106.3% implied volatility (14th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (1.74β · 98% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
DMAC vs RGNX · Reverse Pair
RGNX vs QURE
· Sector Peer
RGNX vs MGTX
· Sector Peer
RGNX vs RARE
· Sector Peer
DMAC vs TRVI
· Sector Peer
DMAC vs VRCA
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem